Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03844048 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
A Phase 3 study of Cancer and Multiple Myeloma, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT03844048 is a Phase 3 study of Cancer and Multiple Myeloma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 165 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT03844048, a Phase 3 study of Cancer and Multiple Myeloma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Conditions Studied
Interventions
- DRUG Venetoclax
Study Locations (20)
New South Wales
- Royal Prince Alfred Hospital /ID# 239557 - Camperdown
- St George Hospital /ID# 225589 - Kogarah
- Liverpool Hospital /ID# 225591 - Liverpool
Western Australia
- Fiona Stanley Hospital /ID# 239480 - Murdoch
- Perth Blood Institute Ltd /ID# 225592 - Nedlands
Arizona
- University of Arizona Cancer Center - Tucson /ID# 210548 - Tucson
California
- UCLA Santa Monica Hematology Oncology /ID# 210551 - Los Angeles
Illinois
- Ingalls Memorial Hosp /ID# 210553 - Harvey
Massachusetts
- Dana-Farber Cancer Institute /ID# 215360 - Boston
Michigan
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132 - Ann Arbor
New Hampshire
- Dartmouth-Hitchcock Medical Center /ID# 210555 - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03844048
The ClinicalTrials.gov registry entry for NCT03844048 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Venetoclax is the first listed.
NCT03844048 reports 20 study locations spanning 17 distinct geographic areas - top geographies include New South Wales, Western Australia, Arizona.
Frequently Asked Questions
What is clinical trial NCT03844048 about?
NCT03844048 is a clinical study titled "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial". The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
What is the current status of trial NCT03844048?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2019-09-06. Estimated completion is 2027-08.
What conditions does trial NCT03844048 study?
This clinical trial studies the following conditions: Cancer, Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT03844048?
The interventions under investigation include: Venetoclax (DRUG).
Who is sponsoring clinical trial NCT03844048?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03844048 being conducted?
This trial has 20 study locations across Arizona, California, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.